{"context":{"query":">>mondo>>gwas_study","source_dataset":"mondo","target_dataset":"gwas_study"},"stats":{"queried":1,"total":89,"mapped":1},"pagination":{"has_next":false},"schema":"id|disease_trait|first_author|journal|publication_date","mappings":[{"input":"MONDO:0005147","source":"MONDO:0005147|type 1 diabetes mellitus","targets":["GCST000038|Type 1 diabetes|Todd JA|Nat Genet|2007-06-06","GCST000043|Type 1 diabetes|Wellcome Trust Case Control Consortium|Nature|2007-06-07","GCST000054|Type 1 diabetes|Hakonarson H|Nature|2007-07-15","GCST000141|Type 1 diabetes|Hakonarson H|Diabetes|2008-01-15","GCST000244|Type 1 diabetes|Grant SF|Diabetes|2008-10-07","GCST000258|Type 1 diabetes|Cooper JD|Nat Genet|2008-11-02","GCST000392|Type 1 diabetes|Barrett JC|Nat Genet|2009-05-10","GCST000539|Type 1 diabetes|Wallace C|Nat Genet|2009-12-06","GCST001191|Type 1 diabetes|Plagnol V|PLoS Genet|2011-08-04","GCST001255|Type 1 diabetes|Bradfield JP|PLoS Genet|2011-09-29","GCST001394|Type 1 diabetes|Huang J|Eur J Hum Genet|2012-02-01","GCST001479|Type 1 diabetes autoantibodies|Howson JM|Diabetologia|2012-04-12","GCST002876|Type 1 diabetes and autoimmune thyroid diseases|Tomer Y|J Autoimmun|2015-04-27","GCST003097|Pediatric autoimmune diseases|Li YR|Nat Med|2015-08-24","GCST005320|Progressive supranuclear palsy and immune-mediated diseases (pleiotropy)|Broce I|PLoS Med|2018-01-09","GCST005321|Amyotrophic lateral sclerosis and immune-mediated diseases (pleiotropy)|Broce I|PLoS Med|2018-01-09","GCST005322|Corticobasal degeneration and immune-mediated diseases (pleiotropy)|Broce I|PLoS Med|2018-01-09","GCST005536|Type 1 diabetes|Onengut-Gumuscu S|Nat Genet|2015-04-01","GCST005563|Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)|Liu JZ|Nat Genet|2013-06-01","GCST006196|Type 1 diabetes in high risk HLA genotype individuals (time to event)|Sharma A|J Autoimmun|2018-01-05","GCST006197|Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)|Sharma A|J Autoimmun|2018-01-05","GCST007247|Latent autoimmune diabetes vs. type 1 diabetes|Cousminer DL|Diabetes Care|2018-09-25","GCST007433|Fulminant type 1 diabetes|Kawabata Y|Diabetes|2018-12-14","GCST008377|Type 1 diabetes|Zhu M|Diabetes Care|2019-05-31","GCST009916|Type 1 diabetes|Onengut-Gumuscu S|Diabetes Care|2019-01-18","GCST010681|Type 1 diabetes|Forgetta V|Diabetes|2020-01-31","GCST011539|Type 1 or type 2 diabetes (pleiotropy)|Inshaw JRJ|Diabetologia|2021-04-08","GCST011773|Type 1 diabetes (age at diagnosis)|Syreeni A|J Intern Med|2020-11-11","GCST012179|Type 1 diabetes|Qu HQ|Commun Biol|2021-07-23","GCST90000181|Type 1 diabetes with low genetic risk score|Qu HQ|Commun Biol|2021-07-23","GCST90000529|Type 1 diabetes|Inshaw JRJ|Diabetologia|2021-04-08","GCST90013445|Type 1 diabetes|Robertson CC|Nat Genet|2021-06-14","GCST90013446|Type 1 diabetes|Robertson CC|Nat Genet|2021-06-14","GCST90013791|Type 1 diabetes|Crouch DJM|Genet Epidemiol|2025-01-01","GCST90013891|Type 1 diabetes (Firth correction)|Mbatchou J|Nat Genet|2021-05-20","GCST90013941|Type 1 diabetes (SPA correction)|Mbatchou J|Nat Genet|2021-05-20","GCST90014023|Type 1 diabetes|Chiou J|Nature|2021-05-19","GCST90014464|Type 1 diabetes|Glanville KP|Biol Psychiatry Glob Open Sci|2021-06-01","GCST90014465|Type 1 diabetes|Glanville KP|Biol Psychiatry Glob Open Sci|2021-06-01","GCST90018705|Type 1 diabetes|Sakaue S|Nat Genet|2021-09-30","GCST90018925|Type 1 diabetes|Sakaue S|Nat Genet|2021-09-30","GCST90043633|Type 1 diabetes with ketoacidosis (PheCode 250.11)|Jiang L|Nat Genet|2021-11-04","GCST90043634|Type 1 diabetes with ophthalmic manifestations (PheCode 250.13)|Jiang L|Nat Genet|2021-11-04","GCST90043635|Type 1 diabetes (PheCode 250.1)|Jiang L|Nat Genet|2021-11-04","GCST90079731|ICD10 E10.3: Type 1 diabetes mellitus with ophthalmic complications|Backman JD|Nature|2021-10-18","GCST90079732|ICD10 E10.9: Type 1 diabetes mellitus without complications|Backman JD|Nature|2021-10-18","GCST90079733|ICD10 E10: Type 1 diabetes mellitus|Backman JD|Nature|2021-10-18","GCST90081525|Probable type 1 diabetes|Backman JD|Nature|2021-10-18","GCST90083717|ICD10 E10.3: Type 1 diabetes mellitus with ophthalmic complications (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90083718|ICD10 E10.9: Type 1 diabetes mellitus without complications (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90083719|ICD10 E10: Type 1 diabetes mellitus (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90085511|Probable type 1 diabetes (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90095483|Type 1 diabetes|Gao Y|World J Diabetes|2021-12-01","GCST90103390|Source of report of E10 (insulin-dependent diabetes mellitus) (UKB data field 130707)|Fitzgerald T|Cell Genom|2022-08-10","GCST90246052|Insulin-dependent diabetes mellitus (Union E10)|Walters RG|Cell Genom|2023-07-20","GCST90281118|Migraine or type 1 diabetes|Islam MR|Hum Genet|2023-02-20","GCST90281125|Headache or type 1 diabetes|Islam MR|Hum Genet|2023-02-20","GCST90281275|Type 1 diabetes|Iakovliev A|Am J Hum Genet|2023-05-04","GCST90297605|ICD10 E10: type 1 diabetes (CNV mirror model)|Auwerx C|Genome Med|2024-01-08","GCST90297659|ICD10 E10: type 1 diabetes (CNV U-shape model)|Auwerx C|Genome Med|2024-01-08","GCST90297708|ICD10 E10: type 1 diabetes (CNV duplication-only model)|Auwerx C|Genome Med|2024-01-08","GCST90297755|ICD10 E10: type 1 diabetes (CNV deletion-only model)|Auwerx C|Genome Med|2024-01-08","GCST90302863|Rheumatoid arthritis or type 1 diabetes|Wen YP|Front Immunol|2023-06-12","GCST90428836|B-cell lymphoblastic leukemia or type 1 diabetes (pleiotropy)|Yu X|BMC Med|2024-04-15","GCST90432064|Type 1 diabetes|Michalek DA|Hum Mol Genet|2024-03-07","GCST90432065|Type 1 diabetes|Michalek DA|Hum Mol Genet|2024-03-07","GCST90432066|Type 1 diabetes|Michalek DA|Hum Mol Genet|2024-03-07","GCST90432067|Type 1 diabetes|Michalek DA|Hum Mol Genet|2024-03-07","GCST90432068|Type 1 diabetes|Michalek DA|Hum Mol Genet|2024-03-07","GCST90435701|Type 1 diabetes (PheCode 250.1)|Zhou W|Nat Genet|2018-08-13","GCST90454277|Insulin-dependent diabetes mellitus|Zeng Y|Am J Psychiatry|2023-04-01","GCST90473169|ICD10 E10: Insulin-dependent diabetes mellitus|UK Biobank Whole-Genome Sequencing Consortium|Nature|2025-08-06","GCST90473170|ICD10 E10: Insulin-dependent diabetes mellitus|UK Biobank Whole-Genome Sequencing Consortium|Nature|2025-08-06","GCST90475659|Type 1 diabetes (PheCode 250.1)|Verma A|Science|2024-07-19","GCST90475660|Type 1 diabetes (PheCode 250.1)|Verma A|Science|2024-07-19","GCST90475661|Type 1 diabetes (PheCode 250.1)|Verma A|Science|2024-07-19","GCST90475663|Type 1 diabetes with ophthalmic manifestations (PheCode 250.13)|Verma A|Science|2024-07-19","GCST90475664|Type 1 diabetes with neurological manifestations (PheCode 250.14)|Verma A|Science|2024-07-19","GCST90477312|Type 1 diabetes with ophthalmic manifestations (PheCode 250.13)|Verma A|Science|2024-07-19","GCST90477313|Type 1 diabetes with neurological manifestations (PheCode 250.14)|Verma A|Science|2024-07-19","GCST90479877|Type 1 diabetes with ophthalmic manifestations (PheCode 250.13)|Verma A|Science|2024-07-19","GCST90479878|Type 1 diabetes with neurological manifestations (PheCode 250.14)|Verma A|Science|2024-07-19","GCST90479879|Type 1 diabetes (PheCode 250.1)|Verma A|Science|2024-07-19","GCST90481579|Type 1 diabetes with ophthalmic manifestations (PheCode 250.13)|Verma A|Science|2024-07-19","GCST90481580|Type 1 diabetes with neurological manifestations (PheCode 250.14)|Verma A|Science|2024-07-19","GCST90492696|Hunner-type interstitial cystitis or type 1 diabetes mellitus (MTAG)|Lyu X|Front Immunol|2024-11-15","GCST90628035|Type 1 diabetes|Hu J|Diabetologia|2025-06-26","GCST90651153|Type 1 diabetes (PheCode 250.1)|Liu TY|Sci Adv|2025-06-04","GCST90667925|ICD10 E10: Insulin-dependent diabetes mellitus|UK Biobank Whole-Genome Sequencing Consortium|Nature|2025-08-06"]}]}